Business
BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA’s Leadership and Next-Generation Innovation
SAN CARLOS, Calif., May 14, 2025--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced it will share data across a range of hematologic malignancies at the European Hematology Association (EHA) Congress in Milan, Italy, June 12–15. BeiGene has 31 abstracts accepted at EHA 2025, with four selected for oral presentations, featuring data from its best-in-class Bruton’s tyrosine kinase (BTK) inhibitor BRUK
About this update from Beone Medicines Ltd. Class A
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1650,"height":310,"url":"https://media.zenfs.com/en/business-wire.com/f33c7962fd55c745f8cd536c9e40ebf9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/92nz.kWNKjOXZiOHGozrcQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/f33c7962fd55c745f8cd536c9e40ebf9","width":960,"height":180},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/e7cfpetWWFjje6xXekER4A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00NTA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/f33c7962fd55c745f8cd536c9e40ebf9","width":1200,"height":225}},"lazy":false},{"type":"text","content":"Data across 31 abstracts illustrate BeiGene’s deep commitment to transforming treatment for B-cell malignancies","length":111,"tagName":"p","attribs":{}},{"type":"text","content":"Four oral presentations highlight updated data from investigational BTK protein degrader BGB-16673 and BCL2 inhibitor sonrotoclax across a range of B-cell malignancies","length":167,"tagName":"p","attribs":{}},{"type":"text","content":"SAN CARLOS, Calif., May 14, 2025--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced it will share data across a range of hematologic malignancies at the European Hematology Association (EHA) Congress in Milan, Italy, June 12–15. BeiGene has 31 abstracts accepted at EHA 2025, with four selected for oral presentations, featuring data from its best-in-class Bruton’s tyrosine kinase (BTK) inhibitor BRUKINSA® (zanubrutinib) and its investigational pipeline assets – a next-generation BCL2 inhibitor, sonrotoclax, and BTK protein degrader, BGB-16673. These data reflect BeiGene’s vision to redefine standards of care in hematology through next-generation science and patient-focused innovation.","length":807,"tagName":"p"},{"type":"text","content":""With three cornerstone hematology assets – BRUKINSA, sonrotoclax and BGB-16673 – we are advancing a potentially best-in-class portfolio in B-cell malignancies," said Lai Wang, Ph.D. Global Head of R&D. "At EHA 2025, we’ll share 31 accepted abstracts that highlight the progress of our hematology clinical development program an...